Hyperammonemia (Acquired)
Overview
Plain-Language Overview
Hyperammonemia is a condition where there is too much ammonia in the blood. Ammonia is a waste product that the body normally removes through the liver. When the liver is damaged or not working properly, ammonia can build up and cause problems. This can lead to symptoms like confusion, tiredness, and in severe cases, swelling of the brain. It is important to understand that hyperammonemia can happen due to different causes, including liver disease or certain medications.
Clinical Definition
Acquired hyperammonemia is characterized by elevated plasma ammonia levels resulting from impaired hepatic clearance or increased ammonia production outside of inherited metabolic defects. It commonly occurs in the setting of acute or chronic liver failure, where hepatocellular dysfunction and portosystemic shunting reduce the liver's ability to convert ammonia to urea via the urea cycle. Ammonia accumulation leads to neurotoxicity, manifesting as altered mental status, asterixis, and in severe cases, cerebral edema and coma. Additional causes include gastrointestinal bleeding, infections, and certain medications that increase ammonia production or decrease its elimination. Diagnosis requires measurement of plasma ammonia concentration, typically exceeding the upper limit of normal (usually >50 µmol/L). The pathophysiology involves disruption of nitrogen metabolism and astrocyte swelling due to glutamine accumulation. Management focuses on identifying and treating the underlying cause, reducing ammonia production, and supporting hepatic function. Understanding the biochemical pathways and clinical consequences is essential for medical students to recognize and manage this potentially life-threatening condition.
Inciting Event
- Acute hepatic decompensation or failure triggers ammonia accumulation.
- Gastrointestinal bleeding increases nitrogen absorption and ammonia production.
- Use of valproic acid or other ammonia-increasing drugs can precipitate symptoms.
- Infections or sepsis may worsen liver function and ammonia clearance.
Latency Period
- Symptoms typically develop within hours to days after the inciting event.
Diagnostic Delay
- Non-specific neurological symptoms such as confusion or lethargy may delay recognition.
- Lack of routine ammonia level testing in altered mental status patients contributes to delay.
- Overlap with other causes of encephalopathy in liver disease complicates diagnosis.
Clinical Presentation
Signs & Symptoms
- Confusion and impaired cognition are early symptoms.
- Lethargy progressing to stupor and coma in severe cases.
- Vomiting and nausea may occur due to cerebral irritation.
- Seizures can develop in advanced hyperammonemia.
- Asterixis is a characteristic motor sign.
History of Present Illness
- Progressive confusion, disorientation, and decreased level of consciousness are common presenting features.
- Patients may report nausea, vomiting, or asterixis (flapping tremor).
- History of recent gastrointestinal bleeding, infection, or medication changes is often elicited.
Past Medical History
- Chronic liver disease such as cirrhosis or hepatitis is frequently present.
- History of urea cycle disorders or metabolic conditions may be relevant.
- Previous episodes of hepatic encephalopathy increase risk of recurrence.
Family History
- Family history of urea cycle disorders or inherited metabolic diseases may be present.
- No direct familial pattern for acquired hyperammonemia related to liver disease.
Physical Exam Findings
- Presence of asterixis (flapping tremor) indicates hepatic encephalopathy.
- Altered mental status ranging from confusion to coma may be observed.
- Signs of liver disease such as jaundice, spider angiomas, and palmar erythema may be present.
- Elevated jugular venous pressure may be noted in cases with underlying cardiac dysfunction.
Diagnostic Workup
Diagnostic Criteria
The diagnosis of acquired hyperammonemia is established by detecting elevated plasma ammonia levels above the normal reference range, typically greater than 50 µmol/L, in the context of clinical features such as altered mental status or encephalopathy. It requires exclusion of inherited urea cycle disorders and correlation with underlying conditions like liver dysfunction or precipitating factors such as gastrointestinal bleeding or infection. Laboratory evaluation includes arterial or venous ammonia measurement, liver function tests, and assessment for precipitating causes. Imaging and neurological assessment may support diagnosis but are not definitive. Prompt recognition of elevated ammonia in symptomatic patients is critical for diagnosis.
Pathophysiology
Key Mechanisms
- Acquired hyperammonemia results from impaired hepatic urea cycle function leading to accumulation of ammonia in the blood.
- Increased ammonia production or decreased clearance due to liver failure or portosystemic shunting causes neurotoxic effects.
- Ammonia crosses the blood-brain barrier causing astrocyte swelling and cerebral edema.
| Involvement | Details |
|---|---|
| Organs | Liver is the primary organ responsible for converting ammonia to urea for excretion. |
| Kidneys contribute to ammonia excretion and acid-base balance. | |
| Brain is affected by elevated ammonia levels causing neurological dysfunction. | |
| Tissues | Liver tissue is essential for ammonia detoxification through the urea cycle. |
| Brain tissue is vulnerable to ammonia toxicity leading to encephalopathy and cerebral edema. | |
| Cells | Hepatocytes are the primary liver cells responsible for ammonia detoxification via the urea cycle. |
| Astrocytes in the brain metabolize ammonia to glutamine, playing a key role in ammonia-induced neurotoxicity. | |
| Chemical Mediators | Ammonia is the toxic metabolite that accumulates in hyperammonemia causing neurological symptoms. |
| Glutamine accumulates in astrocytes during hyperammonemia, contributing to cerebral edema. |
Treatment
Pharmacological Treatments
Lactulose
- Mechanism: Acidifies the colon to convert ammonia to ammonium, reducing absorption
- Side effects: diarrhea, abdominal cramping
Rifaximin
- Mechanism: Non-absorbable antibiotic that reduces ammonia-producing gut bacteria
- Side effects: nausea, abdominal pain
Sodium benzoate
- Mechanism: Conjugates with glycine to form hippurate, facilitating ammonia excretion
- Side effects: nausea, headache
Sodium phenylacetate
- Mechanism: Binds glutamine to form phenylacetylglutamine, excreted in urine, lowering ammonia
- Side effects: metabolic acidosis, nausea
Non-pharmacological Treatments
- Dietary protein restriction to reduce ammonia production from amino acid catabolism.
- Dialysis to rapidly remove ammonia in severe cases of hyperammonemia.
- Liver transplantation in cases of irreversible liver failure causing hyperammonemia.
Prevention
Pharmacological Prevention
- Lactulose reduces ammonia absorption by acidifying the gut and promoting excretion.
- Rifaximin decreases intestinal ammonia-producing bacteria.
- Neomycin is an alternative antibiotic to reduce gut flora producing ammonia.
Non-pharmacological Prevention
- Dietary protein restriction to reduce nitrogen load.
- Avoidance of gastrointestinal bleeding through management of varices and ulcers.
- Prompt treatment of infections to prevent exacerbation of hyperammonemia.
- Regular monitoring of liver function and ammonia levels in at-risk patients.
Outcome & Complications
Complications
- Cerebral edema leading to increased intracranial pressure.
- Hepatic encephalopathy with progressive neurological decline.
- Seizures and status epilepticus.
- Respiratory failure due to decreased consciousness and aspiration risk.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Hyperammonemia (Acquired) versus Hepatic Encephalopathy
| Hyperammonemia (Acquired) | Hepatic Encephalopathy |
|---|---|
| No evidence of liver dysfunction or chronic liver disease | Presence of chronic liver disease signs such as jaundice and ascites |
| Normal liver function tests including bilirubin and coagulation profile | Elevated serum bilirubin and prolonged prothrombin time |
| Hyperammonemia occurs without hepatic structural abnormalities | Imaging showing cirrhotic liver morphology |
Hyperammonemia (Acquired) versus Urea Cycle Disorder (Late-Onset)
| Hyperammonemia (Acquired) | Urea Cycle Disorder (Late-Onset) |
|---|---|
| No prior history of hyperammonemic crises or genetic enzyme defects | History of recurrent hyperammonemic episodes triggered by protein load or stress |
| Normal plasma amino acid profile without urea cycle metabolite abnormalities | Elevated plasma glutamine and low citrulline levels |
| Hyperammonemia associated with acquired conditions such as liver failure or medications | Genetic testing revealing enzyme deficiencies in the urea cycle |
Hyperammonemia (Acquired) versus Valproic Acid Toxicity
| Hyperammonemia (Acquired) | Valproic Acid Toxicity |
|---|---|
| No exposure to valproic acid or related drugs | Recent or ongoing use of valproic acid medication |
| Hyperammonemia due to other acquired causes such as liver failure or infection | Elevated serum valproate levels and associated hepatotoxicity |
| Liver enzymes may be significantly elevated in acute liver failure | Hyperammonemia with normal or mildly elevated liver enzymes |